PT Bio Farma will prepare 3 million doses of the Covid-19 vaccine from Sinovac for health workers, according to the recommendations of a study from the Indonesian Technical Advisory Group on Immunization (ITAGI).

Up to 1.2 million doses of the Covid-19 vaccine arrived in the country last Sunday (12/6), while the remaining 1.8 million doses are projected to arrive in January 2021.

President Director of Bio Farma Honesti Basyir said that the first phase of vaccinations will be provided to health workers in seven provinces in Java and Bali. Vaccinations will then be expanded to non-comorbid healthcare workers in other provinces.

“Vaccines for health workers, of course, shall be provided after an Emergency Use Authorization (EUA) is issued by the Food and Drug Supervisory Agency (BPOM),” he said in an official statement in Bandung last Tuesday (12/8).

Honesti continued to say that this assistance is a form of appreciation for healthcare workers as the frontline in helping to overcome the Covid-19 pandemic.

“Hopefully the presence of the Covid-19 vaccine for healthcare workers can provide security and protection for those who are dealing directly with Covid-19 patients and also provide a sense of security for them,” said Honesti.

Honesti added that all vaccines that will arrive near-term, are the same type of Sinovac vaccine currently being tested in phase three trials in Indonesia, Brazil and several other countries.

“The vaccines we received on December 6, 2020 totaled 1,200,568 vials ready for use, including 568 vials that we will allocate for quality testing which will be carried out at Bio Farma and BPOM.”

“Bio Farma will focus on storing the Covid-19 vaccine and carry out preparations so that it is ready to distribution after obtaining permission for use from BPOM,” said Honesti.

Meanwhile, at the Phase 3 clinical trials held in Bandung, all 1,603 volunteers received a second Covid-19 vaccine injection on November 6, 2020.

Currently, the monitoring and efficacy monitoring stage is underway, 3 months after initial injection to monitor immunogenicity and efficacy, as well as blood testing after 3 months. No serious side effects have been found in volunteers thus far.

Blood samples from volunteers have also been sent to the National Institute of Health Research and Development (Balitbangkes) to be tested against the Covid-19 virus.

The clinical trials team has collected the data needed to provide an interim report to the BPOM, including efficacy data from 1 month after injection and blood collection data 3 months following injection, and is ready to submit the report in mid-January 2021.

Author: HL

Stay updated, subscribe to our newsletter!
Fill in your details below to get our newsletters in your inbox daily.
We respect your privacy.